TCT 2: Two-Year Outcomes in High Bleeding Risk Patients with Bifurcations after Percutaneous Coronary Intervention and One Month Dual Antiplatelet Therapy 

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Consultant Fee/Honoraria/Speaker's Bureau (Personal) - Medtronic; Abbott Vascular; Boston Scientific Corporation; CSI; Siemens; Philips; ReCor Medical; Chiesi; OpSens; Zoll; Regeneron
• Grant Support/Research Contract (Institutional) - Medtronic; Boston Scientific Corporation; Abbott Vascular; Amgen; CSI; Recor Medical; Neurotronic; Biotronik; Chiesi; Bolt Medical; Magenta Medical,; Canon